-
admin
Posts
MRI Software Announces Proposal to Take Private of Singapore-based Anacle
Proposal will expand MRI’s presence in the Asia-Pacific real estate technology market and create future growth opportunities SYDNEY, March 4, 2025 /PRNewswire/ — MRI Software, a...
TECNO Partners with Koç University to Advance Mobile Imaging Aesthetics in Türkiye
BARCELONA, Spain and ISTANBUL, March 4, 2025 /PRNewswire/ — TECNO, an AI-driven technology brand, is teaming up with Koç University in Türkiye, a leading research...
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a...
TCTM Announces the Appointments of Mr. Heng Wang as Chief Executive Officer and Mr. Robert L. Angell as Chief Technology Officer
BEIJING, March 4, 2025 /PRNewswire/ — TCTM Kids IT Education Inc. (NASDAQ: TCTM) (“TCTM” or the “Company“), a leading provider of IT-focused supplementary STEM education...
Starlab Advances to Full Development After Successfully Completing Key NASA Milestone
Full development of the Starlab space station begins following the successful completion of the PDR, ensuring a seamless transition of activity from the International Space...
Global K-Beauty Product Industry Set to Reach USD 20.4 Billion by 2035, Driven by Rising Demand for Korean Skincare Products | FMI
The USA K-beauty product market is expanding rapidly, driven by demand for innovative skincare, clean beauty, and multi-step routines. Consumers value hydrating formulas and dermatologically...
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event...
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
– Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile – – MAD study initiated in patients with...
Dingdong to Report Fourth Quarter 2024 Financial Results on March 6, 2025
SHANGHAI, March 3, 2025 /PRNewswire/ — Dingdong (Cayman) Limited (“Dingdong” or the “Company”) (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced...
Exclusive Markets Opens Dubai Rep. Office and Launches a Special Ramadan Promotion
DUBAI, UAE, March 3, 2025 /PRNewswire/ — Exclusive Markets has officially opened its new representative office in Dubai. To celebrate this significant milestone, they are offering a...
